Clinical Implications and Implementation

In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them?

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CMEs: Quick Take Vol. 78
• Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial